Gb Sciences Achieves Positive Proof-of-Concept Results for Their Cytokine Release Syndrome Therapies Designed to Suppress COVID-Related Hyperinflammation LAS VEGAS, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Gb Sciences, Inc. (OTCQB: GBLX) received positive proof-of-concept data from a human immune cell model supporting their proprietary...

Gb Sciences Presenting COVID-Related Cytokine Release Syndrome Results at H.C. Wainwright's 23rd Annual Global Investment Conference LAS VEGAS, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired biopharmaceutical development company, today announced that their President and Chief Science...